Tapentadol

Routes
Oral (PO)
Half-Life (t½)
PO: 4h
Formula
C14H23NO
Molecular Weight
221.34 g/mol
PubChem CID
9838022
Aliases
Nucynta

Pharmacological Mechanism

Centrally-acting μ-opioid agonist + norepinephrine reuptake inhibitor — dual mechanism gives analgesic effect with lower opioid receptor occupancy than equipotent morphine, reducing GI side effects. Schedule II. CYP-independent metabolism (UGT2B7) limits DDI footprint.

Half-Life & Elimination Curve (PO: 4h)

100%50%25%12.5%0%0h0×t½4h1×t½8h2×t½12h3×t½16h4×t½20h5×t½0×t½ (0h): 100% remaining (~44.7 µg/L)1×t½ (4h): 50% remaining (~22.4 µg/L)2×t½ (8h): 25% remaining (~11.2 µg/L)3×t½ (12h): 12.5% remaining (~5.59 µg/L)4×t½ (16h): 6.3% remaining (~2.79 µg/L)5×t½ (20h): 3.1% remaining (~1.4 µg/L)
Plasma (PO)t½ Decay (4h)Effect Site (ke0)
  • 0×t½0h100% (44.7 µg/L)
  • 1×t½4h50% (22.4 µg/L)
  • 2×t½8h25% (11.2 µg/L)
  • 3×t½12h12.5% (5.59 µg/L)
  • 4×t½16h6.3% (2.79 µg/L)
  • 5×t½20h3.1% (1.4 µg/L)
Elimination t½4h (PO)
Rate Constant (ke)0.173 h⁻¹
Time to Peak (Tmax)1.63h
Est. Peak (Cmax)44.7 µg/L
Clearance (CL)93.6 L/h
97% Washout (5×t½)20h

Dosing Guidelines

Pharmacokinetic Parameters

Receptor Binding & Occupancy

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References